I don’t think GTC’s Friday PR changes anything of consequence. We already knew that several of the purported programs in the company’s portfolio—most notably ATryn for DIC/sepsis—were vaporware.
LFB now has control of the BoD and they can do whatever they want with GTC whenever they want to. I can’t see any plausible outcome that is beneficial for the minority shareholders. Regards, Dew
News 
Market Data 
Discover 
AI
